Nabi Biopharmaceuticals Announces Initiation Of Civacir(R) Phase II 'Proof-of- Concept' Clinical Trial

Wed, 17 Jan 2007 02:00 PM EST

... Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that it has initiated its Phase II "proof-of-concept" clinical trial for Civacir(R) [Hepatitis C Immune Globulin (Human)]. [click link for full article] ...